Lundbeck suffers Flurizan profit blow
This article was originally published in Scrip
The clinical failure of Flurizan (tarenflurbil) hit Lundbeck heavily as charges relating to the drug more than halved the firm's second quarter net profit. The Danish company's profit fell by 52% to DKK240 million ($47.9 million) following a DKK481 million writedown related to the Alzheimer's disease candidate.
You may also be interested in...
AB Science has closed its IPO at just half of the value of its initial expectations. The gross proceeds of the French firm's offer were €27.5 million, compared with the €55.5 million it anticipated when it filed for the offering on 8 April. Of the total, the company secured $16.5 million from the sale of newly issued shares; the remaining €11 million went to selling shareholders.
Amgen's sales rebounded in the first quarter rising 9% to $3.6 billion after a disappointing end to last year. However, the introduction of new legislation for US healthcare has weighed on its forecast for the year, as it has done for many of its competitors.
Actelion's total revenues leapt up by 24% to CHF502 million ($467 million) during the first quarter due to stronger demand for its pharmaceuticals. The firm's net income rose by 30% to CHF133 million, while its diluted EPS increased from CHF0.83 in the first quarter last year to CHF1.09.